

KEYSTONE SYMPOSIA

on Molecular and Cellular Biology

Antibodies as Drugs: From B Cell Biology to New Treatments (B1)

February 2-6, 2020 • Eldorado Hotel & Spa • Santa Fe, NM, USA

Scientific Organizers: Paul Carter, Janine Schuurman and Karl Dane Wittrup

Sponsored by BioLegend, Inc., Compass Therapeutics, Incyte Corporation, MorphoSys AG and Surface Oncology

Supported by a grant from Genentech

Discounted Abstract & Scholarship Deadline: October 17, 2019 / Abstract Deadline: November 5, 2019 / Discounted Registration Deadline: December 5, 2019

SUNDAY, FEBRUARY 2

Arrival and Registration

MONDAY, FEBRUARY 3

Welcome and Keynote Address

Glenn Dranoff, Novartis Institutes for BioMedical Research, USA
Future Prospects for Cancer Immunotherapy

Immunoglobulin Repertoires: From Basic Biology to Therapeutic Applications

Pierre Bruhns, Institut Pasteur, France
Deep-Mining of Antibody Repertoires for Diagnostics and Therapeutic Antibody Discovery

Ning Jenny Jiang, University of Texas at Austin, USA
Systems Immunology Based Immune Engineering

Sai T. Reddy, ETH Zurich, Switzerland
Antibody Discovery and Engineering by Deep Learning

Short Talks Chosen from Abstracts

Poster Session 1

Workshop 1

Short Talks Chosen from Abstracts

Biology of Antibody Generation by B Cells

Facundo D. Batista, Ragon Institute of MGH, MIT and Harvard, USA
B Cell Activation: From Molecular Events to Antibody Production

Daniel Christ, Garvan Institute of Medical Research, The University of New South Wales, Australia
Stability and Specificity Engineering of the Human Antibody Repertoire

Shane Crotty, La Jolla Institute for Immunology, USA
Probing the Human Naive B Cell Repertoire, and Developing Immunization Strategies that Enhance Antibody and Germinal Center Responses via Modulation of Immunodominance

Short Talks Chosen from Abstracts

TUESDAY, FEBRUARY 4

Advances in Antibodies for Immuno-Oncology

Teemu T. Junttila, Genentech, Inc., USA
Optimization of Preclinical Safety and Efficacy of anti-HER2/CD3 TDB

Esther Breijl, Genmab, Netherlands
Boosting Anti-Tumor Immunity using Bispecific Antibody Molecules

Nicolas Fischer, Novimmune SA, Switzerland
Harnessing Macrophage Activity via Targeted Inhibition of the CD47-SIPRa Axis

Jennifer E. O'Neil, Akreva Therapeutics, USA
Development of a Highly Potent anti-CTLA-4 Antibody Active Specifically in the Tumor Microenvironment

Short Talks Chosen from Abstracts

Pharmacology of Antibody Drugs

Amrita Kamath, Genentech, Inc., USA
PK/PD Considerations for the Development of T-cell Dependent Bispecific Antibodies

Tim Paul Hickling, Pfizer, Inc., USA
Mechanistic, Multiscale Mathematical Model of Immunogenicity for Therapeutic Proteins

Dhaval K. Shah, University at Buffalo, USA
Tissue Distribution of Antibodies: Pharmacokinetics/Pharmacodynamics Perspective

Short Talks Chosen from Abstracts

Poster Session 2

WEDNESDAY, FEBRUARY 5

Antibody Effector Functions

Piet Gros, Utrecht University, Netherlands
Molecular Mechanisms of Antibody-Mediated Complement Activation

Leo James, MRC Laboratory of Molecular Biology, UK
Targeted Protein Depletion using Cytosolic Antibodies

Falk Nimmerjahn, Universitätsklinikum Erlangen, Germany
Tumor-Associated Macrophages and Antibody-Dependent Immunotherapy Response

Marjolein van Egmond, VU University Medical Center, Netherlands
IgA as Therapeutic Antibodies 2.0?

Short Talks Chosen from Abstracts

T Cell Targeting for Cancer Therapy

Thorald van Hall, Leiden University Medical Center, Netherlands
CD3-Engagement in the Tumor Microenvironment

Angela Coxon, Amgen Inc., USA
Targeting T Cells to Solid Tumors using BiTE® Molecules

Harpreet Singh, Immatics Biotechnologies, Germany
TCR-Based Cancer Immunotherapies to Novel pMHC Targets

Short Talks Chosen from Abstracts

THURSDAY, FEBRUARY 6

Antibodies for the Treatment of Infectious Diseases

Laura M. Walker, Adimab LLC, USA
Longitudinal Dynamics of the Human B Cell Response to the Yellow Fever 17D Vaccine

Sanjay Ram, University of Massachusetts, USA
DNA-Encoded Anti-Lipooligosaccharide Monoclonal Antibody Engineered to Enhance Complement Activation as a Vaccination Strategy against Multidrug-Resistant Gonorrhea

Robert A. Seder, NIAID, National Institutes of Health, USA
A Human Monoclonal Antibody Prevents Malaria Infection by Targeting a New Site of Vulnerability on the Parasite

Galit Alter, Ragon Institute of MGH, MIT, and Harvard, USA
A Systems Fc-Engineering Approach to Define Functional Humoral Correlates of Immunity

Short Talks Chosen from Abstracts

Workshop 2

KEYSTONE SYMPOSIA

on Molecular and Cellular Biology

Antibodies as Drugs: From B Cell Biology to New Treatments (B1)

February 2-6, 2020 • Eldorado Hotel & Spa • Santa Fe, NM, USA

Scientific Organizers: Paul Carter, Janine Schuurman and Karl Dane Wittrup

Sponsored by BioLegend, Inc., Compass Therapeutics, Incyte Corporation, MorphoSys AG and Surface Oncology

Supported by a grant from Genentech

Discounted Abstract & Scholarship Deadline: October 17, 2019 / Abstract Deadline: November 5, 2019 / Discounted Registration Deadline: December 5, 2019

Short Talks Chosen from Abstracts

Emerging Antibody Drugs for Neurodegenerative, Cardiovascular and Immunological Diseases

Tina Schwabe, Alector, USA

Immune Modulatory Antibody Drugs for Dementia

Jamie M. Orengo, Regeneron Pharmaceuticals Inc., USA

Novel Approaches to Treating Allergic Disorders with Monoclonal Antibodies

Short Talk Chosen from Abstracts

Meeting Wrap-Up: Outcomes and Future Directions (Organizers)

FRIDAY, FEBRUARY 7

Departure